Biotech firm backs off its focus on oncology research
IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...
Business Insider3d
IGM Biosciences price target raised to $27 from $25 at Stifel
Stifel raised the firm’s price target on IGM Biosciences (IGMS) to $27 from $25 and keeps a Buy rating on the shares. The firm believes management’s ability to provide a preliminary mid-FY25 update ...
Cautious Outlook for IGM Biosciences Amid Delayed Data and Financial Adjustments
Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...
TipRanks on MSN6d
IGM Biosciences Shifts Focus to Autoimmunity
Igm Biosciences ( ($IGMS) ) has released its Q3 earnings. Here is a breakdown of the information Igm Biosciences presented to ...
ETF Daily News5d
IGM Biosciences (NASDAQ:IGMS) Trading Down 7.8% – Should You Sell?
Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) dropped 7.8% on Friday .The stock traded as low as $12.82 and last traded at $13.25. Approximately 108,339 shares changed hands ...
Morningstar7d
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial ...
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...
Yahoo Finance6d
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...